Drugs / POMx
POMx
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT01220206 | Aug 2011 → Oct 2012 | erectile dysfunction | POM Wonderful LLC | Completed | No outcome recorded |
| Phase 2 | NCT01220817 | Oct 2007 → May 2010 | prostate carcinoma | POM Wonderful LLC | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT00470808 | May → Aug 2007 | atherosclerosis | HaEmek Medical Center, Israel | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT02949583 | Mar → May 2012 | gingivitis | Universidade Estadual da Paraiba | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03772418 Comparator | May 2018 → Jan 2020 | — | Al-Azhar University | Unknown | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | POMx | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01220206 ↗ |
| Known as | Pomegranate | “The extracts of ginkgo biloba and Pomegranate as formulated in topical dosage form will be applied to the 30 aging people who are suffering from wrinkles in the skin male and female.” NCT03772418 ↗ |
| Known as | pomegranate extract | “This study assesses biological activity of two doses of pomegranate extract (POMx) in men with recurrent prostate cancer” PMID 22689129 ↗ Jun 2012 |
| Known as | Punica granatum Linn. | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02949583 ↗ |
| Action | Activate | “to potentiate the biologic activity of the enzyme paraoxonase 1” NCT00470808 ↗ |
| Route | Oral | “One POMx capsule, one placebo capsule daily” NCT01220206 ↗ |